Obesity negatively impacts maintenance of antibody response to COVID-19 vaccines.
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
18 07 2023
18 07 2023
Historique:
received:
17
06
2023
revised:
19
06
2023
accepted:
21
06
2023
medline:
21
7
2023
pubmed:
20
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
Severe obesity accelerates the decline of neutralizing antibodies to COVID-19 vaccines contributing to increased risk of hospitalization from breakthrough SARS-CoV-2 infections.
Identifiants
pubmed: 37467723
pii: S2666-3791(23)00245-8
doi: 10.1016/j.xcrm.2023.101117
pmc: PMC10394250
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101117Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests Authors declare that they have no competing interests.
Références
Nat Med. 2023 May;29(5):1146-1154
pubmed: 37169862
Int J Obes (Lond). 2012 Aug;36(8):1072-7
pubmed: 22024641
Clin Exp Immunol. 2022 Dec 31;210(3):263-272
pubmed: 35960996
Vaccine. 2017 May 9;35(20):2694-2700
pubmed: 28392139
Cell Metab. 2022 Jan 4;34(1):1-2
pubmed: 34895500
Autoimmunity. 2006 Mar;39(2):137-41
pubmed: 16698670
Front Endocrinol (Lausanne). 2020 Dec 21;11:595109
pubmed: 33408692
Microbiol Spectr. 2023 Jun 15;11(3):e0001023
pubmed: 37098954
Int J Obes (Lond). 2021 Jul;45(7):1521-1531
pubmed: 33941843
Cell Rep. 2022 Dec 13;41(11):111799
pubmed: 36493786